共 50 条
Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus
被引:12
|作者:
Peschken, Christine A.
[1
,2
]
Wang, Yishu
[3
]
Abrahamowicz, Michal
[3
]
Pope, Janet
[4
,5
]
Silverman, Earl
[6
,7
]
Sayani, Amyn
[8
]
Iczkovitz, Sandra
[8
]
Ross, Jorge
[9
]
Zummer, Michel
[10
]
Tucker, Lori
[11
]
Pineau, Christian
[12
]
Levy, Deborah
[6
,7
]
Hudson, Marie
[13
,14
]
Hitchon, Carol A.
[1
]
Huber, Adam M.
[15
,16
]
Smith, C. Douglas
[17
]
Avina-Zubieta, Antonio
[18
]
Arbillaga, Hector
[19
]
Chedeville, Gaelle
[20
]
Wynant, Willy
[3
]
Fortin, Paul R.
[21
]
机构:
[1] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada
[2] Univ Manitoba, Dept Community Hlth, Winnipeg, MB, Canada
[3] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[4] Univ Western Ontario, London, ON, Canada
[5] St Josephs Hlth Care London, London, ON, Canada
[6] Hosp Sick Children, Toronto, ON, Canada
[7] Univ Toronto, Toronto, ON, Canada
[8] GlaxoSmithKline Inc, Med Affairs, Mississauga, ON, Canada
[9] GlaxoSmithKline Inc, King Of Prussia, PA USA
[10] Maisonneuve Rosemont, Montreal, PQ, Canada
[11] BC Childrens Hosp, Vancouver, BC, Canada
[12] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[13] Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ, Canada
[14] McGill Univ, Montreal, PQ, Canada
[15] IWK Hlth Ctr, Halifax, NS, Canada
[16] Dalhousie Univ, Halifax, NS, Canada
[17] Univ Ottawa, Ottawa, ON, Canada
[18] Univ British Columbia, Div Rheumatol, Arthrit Res Canada, Vancouver, BC, Canada
[19] Rheumatol Clin, Calgary, AB, Canada
[20] McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Montreal, PQ, Canada
[21] Univ Laval, CHU Quebec, Dept Med, Div Rheumatol, Laval, PQ, Canada
关键词:
SYSTEMIC LUPUS ERYTHEMATOSUS;
DISEASE ACTIVITY;
1000 CANADIAN FACES;
DOUBLE-BLIND;
SOCIOECONOMIC-STATUS;
ORGAN DAMAGE;
ACTIVITY INDEX;
ACTIVITY STATE;
EFFICACY;
SAFETY;
COHORT;
HEALTH;
D O I:
10.3899/jrheum.171454
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective. Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality. In a multicenter cohort of patients with prevalent SLE, we described persistence, patterns, and predictors of change in disease activity over time. Methods. Based on SLE Disease Activity Index (SLEDAI)-2K scores at cohort entry, patients were classified into 4 groups: low (score < 4; LOW), moderate (4 to < 6; MOD), moderately high (6 to <= 10; MHIGH), and very high (> 10; VHIGH). Multivariable linear and longitudinal mixed linear regression models were used to identify predictors of change over time in SLEDAI-2K. Results. There were 2019 participants, with declining followup data over 5 years (1326, 580, 274, 186, and 148 patients, respectively). At cohort entry, mean (+/- SD) age was 42 (+/- 17) years, disease duration 11 (+/- 10) years, and 90% were female. The 4 groups included 44% LOW (n = 891), 20% MOD (n = 400), 22% MHIGH (n = 442), and 14% VHIGH (n = 286); therefore, 36% had clinically important SLE activity. The proportion of patients in the LOW group at entry who moved to a higher activity level varied from 30% (167/557) at 1 year, to 49% (41/83) at 3 years, and 54% (30/56) at 5 years. Among 181 patients with MOD to VHIGH entry activity and 3 years of followup, 116 (64.1%) remained active. In all analyses, only higher SLEDAI-2K at cohort entry remained a significant predictor of higher SLEDAI-2K in subsequent years. Conclusion. Higher SLEDAI-2K at study entry was the single major independent predictor of higher SLEDAI-2K over time, reflecting frequent persistence of active disease, even in patients with longstanding disease. This highlights gaps in the optimal treatment of SLE.
引用
收藏
页码:166 / 175
页数:10
相关论文